Vitamin D status and bone biomarkers in childhood cancer

Pediatric Blood and Cancer

Volumn 50, Issue 2 SUPPL., 2008, Pages 479-482

  Atkinson, Stephanie A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone biomarkers; Vitamin D

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; GLUCOCORTICOID; LEPTIN; METHOTREXATE; OSTEOCALCIN; PARATHYROID HORMONE; SOMATOMEDIN C; VITAMIN D;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; BIOCHEMISTRY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CHILDHOOD CANCER; EARLY DIAGNOSIS; HORMONE ACTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; BONE AND BONES; CHILD; ENDOCRINE SYSTEM; HUMANS; NEOPLASMS; PARATHYROID HORMONE; VITAMIN D;

EID: 37548999391     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21406     Document Type: Review

References (29)

1. van der Sluis IM. Osteoporosis in children with cancer. Pediatr Blood Cancer (in press).
2. Lehtonen-Veromaa MK, Mottonen TT, Nuotio IO, et al. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: A3-y prospective study. Am J Clin Nutr 2002;76:1446-1453.
3. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2000;30:771-777.
4. Guillemant J, Cabrol S, Allemandou A, et al. Vitamin D-dependent seasonal variation of PTH in growing male adolescents. Bone 1995;17:513-516.
5. Halton JM, Atkinson SA, Fraher L, et al. Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr 1995;126:557-564.
6. Arikoski P, Komulainen J, Riikonen P, et al. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: A 1 -year prospective study. J Clin Endocrinol Metab 1999;84:3174-3181.
7. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, et al. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 2002;141:204-210.
8. van der Sluis IM, Hop WC, van Leeuwen PTM, et al. A cross-sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy Dutch children and young adults. Hormone Res 2002;57:170-179.
9. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11:1774-1783.
10. Chesney RW, Mazess RB, Hamstra AJ, et al. Reduction of serum 1,25 dihydroxy vitamin D3 in children receiving glucocorticoids. Lancet 1978;2:1123-1125.
11. Godschalk M, Levy JR, Downs RW. Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J Bone Miner Res 1992;7:21-26.
12. Othman F, Guo CY, Webber C, et al. Osteopenia in survivors of Wilms tumor. Int J Oncol 2002;20:827-833.
13. Marinovic D, Dorgeret S, Lescoeur B, et al. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: A 1 -year prospective study. Pediatrics 2005;116:e102-e108.
14. Alikasifoglu A, Yetgin S, Cetin M, et al. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: Comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol 2005;80:113-118.
15. Atkinson SA, Halton JM, Bradley C, et al. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: Influence of disease, drugs and nutrition. Int J Cancer 1998; Suppl. 11:35-39.
16. Bath LE, Crofton PM, Evans AEM, et al. Bone turnover and growth during and after chemotherapy in children with solid tumors. Pediatr Res 2004;55:224-230.
17. Guo CY, Weiler H, Atkinson SA. Elevated intact parathyroid hormone is associated with reduced biochemical markers of bone formation and resorption measured in blood in infant piglets receiving oral dexamethasone for 15 days. Biol Neonate 2001;80:295-299.
18. Hoorweg-Nijman JJG, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxford) 1999;50:237-244.
19. Sala A, Talsma D, Webber C, et al. Bone mineral status after treatment of malignant lymphoma in childhood and adolescent. Eur J Cancer Care 2007;16:373-379.
20. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.
21. Conover CA. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-studies of underlying mechanism. Endocrinology 1992;130:191-199.
22. Ranke MB, Schweizer R, Lindberg A, et al. Insulin-like growth factors as diagnostic tools in growth hormone deficiency during childhood and adolescence: The KIGS experience. Hormone Res 2004;62:17-25.
23. Lofqvist C, Anderson E, Gelander L, et al. Reference values for insulin-like growth factor binding protein 3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBPs throughout childhood and adolescence. J Clin Endocrinol Metab 2005;90:1420-1427.
24. Elmlinger MW, Kuhnel E, Weber MM, et al. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654-664.
25. Brennan BM, Pennells L, Eden OB, et al. Insulin-like growth factor I, IGF binding protein 3, and IGFBP protease activity: relation to anthropometric indices in solid tumours or leukaemia. Arch Dis Child 1999;80:226-230.
26. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002;17:1563-1569.
27. Brennan BMD, Rahim A, Blum WF, et al. Hyperleptinaemia in young adults following cranial irradiation in childhood: Growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxford) 1999;50:163-169.
28. Bülow B, Link K, Ahrén B, et al. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxford) 2004;61:683-691.
29. Yaris N, Sözen E, Erduran E, et al. Bone mineral metabolism and its relationship to leptin levels in survivors of childhood leukemia and lymphoma. Pediatr Hematol Oncol 2005;22:489-498.